Legend Biotech Q2 2026: CARVYKTI Sales Surge 50% to $657M, Company Swings to Profit

summarizeSummary

Legend Biotech reported Q2 2026 earnings with CARVYKTI sales up 50% to $657M, driving a net profit of $33.2M. The company also unveiled promising early data for its in vivo CAR-T platform and strengthened its cash position to $965M.

check_boxKey Events · Earnings and Guidance · LEGN

• CARVYKTI Sales Surge 50%

  Q2 2026 CARVYKTI net trade sales reached approximately $657 million, up 50% year-over-year, with U.S. growth of 32% and ex-U.S. growth of 128%.

• Company Swings to Profitability

  Net income was $33.2 million in Q2 2026, compared to a $125.4 million loss in Q2 2025. Adjusted net income was $63.1 million, driven by higher gross profit from CARVYKTI.

• LB2501 In Vivo CAR-T Shows 100% ORR

  First clinical proof-of-concept for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T, achieved 100% overall response rate and 83.3% complete response at the higher dose level in relapsed/refractory B-cell NHL.

• Strong Cash Position of $965M

  Cash and cash equivalents plus time deposits totaled approximately $965 million as of June 30, 2026, bolstered by a $212 million net proceeds from a public offering in June.

auto_awesomeAnalysis · LEGN · Life Sciences

A breakout quarter saw Legend Biotech swing to a net profit of $33.2 million from a $125.4 million loss a year ago, fueled by a 50% surge in CARVYKTI net trade sales to approximately $657 million. Compelling early clinical data for the next-generation in vivo CAR-T therapy LB2501 showed a 100% overall response rate at the higher dose. With $965 million in cash and equivalents, the balance sheet is strong, and management reiterated confidence in achieving company-wide profitability in 2026. The only new risk factor highlights ongoing tax negotiations in China that could impact future cash flows, but the overall picture is one of accelerating commercial momentum and pipeline validation.